Literature DB >> 19253934

CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature.

Anjali P Kusumbe1, Avinash M Mali, Sharmila A Bapat.   

Abstract

Recruitment and localization of endothelial precursors within tumors is a potential area for the development of therapeutics, because their functional contribution to tumor vasculature is realized to be important for cancer cell survival. However, the exact nature of the recruited cell type and cellular events orchestrating the entire phenomenon remains obscure. We report that human ovarian cancer is frequently associated with cells expressing the stem cell surface marker CD133. We further show that these CD133-expressing cells are nontumorigenic in nature, and they augment tumor development through their vasculogenic potential. This cell population is attracted by cancer stem cells (CSCs) and retains a direct physical association within the CSC-derived spheroids. Our study further delineates the contribution of these vasculogenic CD133(+) stem cells, termed by us as endothelial stem cells (EnSCs) to the developing tumor vasculature during disease progression. In support of their being stem cells, the EnSCs have a capability of establishing an entire endothelial cell hierarchy. We conclude that such EnSCs play a crucial role in ensuring the development of long-term tumor vasculature to complement CSC-driven tumor development and disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253934     DOI: 10.1634/stemcells.2008-0868

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  31 in total

1.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

2.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

3.  Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.

Authors:  Sharmila A Bapat; Victor Jin; Nicholas Berry; Curt Balch; Neeti Sharma; Nawneet Kurrey; Shu Zhang; Fang Fang; Xun Lan; Meng Li; Brian Kennedy; Robert M Bigsby; Tim H M Huang; Kenneth P Nephew
Journal:  Epigenetics       Date:  2010-11-01       Impact factor: 4.528

Review 4.  Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Authors:  Christen L Walters Haygood; Rebecca C Arend; J Michael Straughn; Donald J Buchsbaum
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 5.  Ovarian cancer stem cells: are they real and why are they important?

Authors:  Monjri M Shah; Charles N Landen
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

Review 6.  CD133-targeted niche-dependent therapy in cancer: a multipronged approach.

Authors:  Anthony B Mak; Caroline Schnegg; Chiou-Yan Lai; Subrata Ghosh; Moon Hee Yang; Jason Moffat; Mei-Yu Hsu
Journal:  Am J Pathol       Date:  2014-02-28       Impact factor: 4.307

7.  A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.

Authors:  R R Naik; A K Singh; A M Mali; M F Khirade; S A Bapat
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Isolation and identification of cancer stem-like cells from side population of human prostate cancer cells.

Authors:  Yatong Chen; Jiahui Zhao; Yong Luo; Yongxing Wang; Nengbao Wei; Yongguang Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

Review 9.  Advances in complex multiparameter flow cytometry technology: Applications in stem cell research.

Authors:  Frederic Preffer; David Dombkowski
Journal:  Cytometry B Clin Cytom       Date:  2009-09       Impact factor: 3.058

10.  Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.

Authors:  T Xiang; H Long; L He; X Han; K Lin; Z Liang; W Zhuo; R Xie; B Zhu
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.